European Medicines Agency Revises Orphan Drugs Policy - - BioPharm International

ADVERTISEMENT

European Medicines Agency Revises Orphan Drugs Policy


The European Medicines Agency has revised its policy on fee reductions for orphan drugs.  The changes provide enhanced fee reductions for companies that are not micro, small, or medium-sized enterprises (SMEs) and will take affect on January 1, 2014. The policy will continue to focus on assistance to SMEs with the objective of providing incentives to support research and innovation on medicines intended for the diagnosis, prevention, or treatment of rare diseases, as recommended by EMA’s Committee for Orphan Medicinal Products (COMP). Current fee-reduction rates will still apply to applications received by EMA until Dec. 31, 2013.
 
EMA has listed the following fee reductions for non-SMEs in 2014:

  • 75% fee reduction for non-pediatric-related initial and follow-up protocol assistance (currently a 40% fee reduction)
  • 100% fee waiver for pediatric-related initial and follow-up protocol assistance (no change from 2013)
  • 10% fee reduction for initial marketing-authorization applications (currently no fee reduction)
  • 100% fee reduction for pre-authorization inspections (currently no fee reduction).

The following services will remain free-of-charge for SMEs in 2014:

  • All initial and follow-up protocol assistance
  • Initial marketing-authorization applications
  • Pre-authorization inspections
  • Post-authorization applications and annual fees in the first year of marketing authorization.

Source: European Medicines Agency

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here